Tag Archives: competition

Are pharmaceutical mega-mergers in the public interest?

The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development –  R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading

Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.

David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading

Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Pharmaceutical R & D – the value of radical innovation versus incremental progress

What we really want is affordable products that benefit patients, whether or not they are “innovative” in the usual sense of the word. Scientific innovation is not a medical end in itself. The ultimate aim of pharmaceutical R&D is to … Continue reading

Posted in Business, competition, Department of Health, Drugs, Emerging technologies, Finance, Healthcare, Innovation, NHS, Patients, Pharma, Policy, Research, Technology, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

The Health and Social Care Bill: Final Stages in Parliament

With opposition to the Health and Social Care Bill having reached new heights, we must look behind the rhetoric and remember basic principles. The most important point to remember is that the NHS exists to provide the best possible, affordable … Continue reading

Posted in Andrew Lansley, Business, Commissioning, competition, David Cameron, Department of Health, GPs, Health Bill, Hospitals, Inequality, NHS, Patient choice, Patients | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Misleading, Biased Reporting on the Health and Social Care Bill in the Media

Above all the freedom of the Press is paramount. Censorship or severely restrictive legislation is not an acceptable alternative. We sometimes have to accept the consequences and tolerate a Press that can be wrong, unfair, misleading or more interested in … Continue reading

Posted in Andrew Lansley, competition, David Cameron, Department of Health, equality, Finance, Health Bill, Hospitals, Inequality, NHS, Patients, Private | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | 5 Comments

Patients to access their own medical records by 2015

Earlier this week during the chancellor of the exchequer’s autumn financial statement, it was announced that not only will patients have online access to their medical records from 2015, but they will be able to see data on GP performance … Continue reading

Posted in Andrew Lansley, competition, Information, Policy | Tagged , , , | Leave a comment

Parallel importing and exporting of pharmaceuticals severely limits the options in designing an effective UK drug pricing scheme.

A fundamental principle of the EU is the establishment of a single market where products can be freely imported and exported between member states. In the case of pharmaceuticals this ideal conflicts with the freedom of individual countries to fix … Continue reading

Posted in Business, competition, Department of Health, Drugs, Innovation, NHS, Pharma, Policy, Research | Tagged , , , , , , , , , , , , , , , , , , , , , | 1 Comment